Friday, 20 Oct 2017

Today's Headlines

Tofacitinib Scores in TNF inhibitor Resistant Psoriatic Arthritis

Mease et al has reported in the NEJM the results of a phase 3 trial showing tofacitinib (Tofa) to be significantly more effective than placebo in active psoriatic arthritis (PsA) patients who previously failed to respond to tumor necrosis factor inhibitor (TNFi) therapies. 

Gout Increases Risk of Stroke Moreso than MI

Gout coassociates with many of the disorders within the metabolic syndrome - diabetes, hypertension, hyperlipidemia and obesity.  Not surprisingly, gout is a risk factor for cardiovascular disease, but the risk magnitude for  myocardial infarction (MI), and stroke are unclear.

Stelara FDA Approved for Use in Adolescent Psoriasis

Johnson & Johnson has announced that they have received an expanded FDA approval for the use of ustekinumab (Stelara) in treating adolescent patients, aged 12 and over, with moderate to severe plaque psoriais.

High Drug Discontinuations and Nonadherence in Fibromyalgia

Compliance and adherence was shown to be quite poor in fibromyalgia (FM) patients, with high rates of drug discontinuation and greater than 60% demonstrated low adherence.

Spinal X-ray Inhibition in Ankylosing Spondylitis Best Achieved by Control of Activity

Although tumour necrosis factor inhibitors (TNFi) are highly effective (on clinical grounds) in ankylosing spondylitis (AS), proof that they may alter the course of spinal radiographic progression has been scant. That's primarily because of the insidisous nature of the disease, comparatively slow progression and difficulties in imaging and scoring the sacroiliac and axial joints. 

BLOG

I recently had a follow up with an SLE patient who wanted to discuss sun protection options since moving to Dallas, where we have 232 days of sunshine yearly. Sun protection is important for our patients. As rheumatologists, we have an obligation to go beyond 'avoid the sun or wear sunscreen when you're out' platitudes.

The antiphospholipid syndrome (APS) is a common disorder affecting patients with and without autoimmune disease. Despite wider recognition of APS among physicians as well as the expanding research collaborations, many clinical questions are still encountered in clinical practice, which require further evidence-based studies. In this “Across the Table” edition, Drs. Cush and Erkan discuss some of these APS-related questions. Our guest expert, Dr. Doruk Erkan offers up his approach to diagnosis and management of APS.

A new patient came in today; he noted that he made an appointment with me after reading a favorab

Everyone gets their education about drug-related infection risk from television ads. Rheumatologists should know what the real risks are and educate their patients that they have a higher than normal rate of nonserious infections. But the infection risk is way more related to inflammation than any specific drug risk.

Today in clinic, I saw a patient with longstanding seropositive, erosive rheumatoid arthritis who

Dr. Olga Petryna - Ustekinumab in Psoriatic Enthesitis
Dr. Petryna is at EULAR 2017 in Madrid.
/vef/load/de43f7407f7582571e34a0247b090e66?width=640&height=365

Social

30% off use code RWCS2018ACR

Daily Download

How Rheumatologists Diagnose and Treat RA